Skip to main content
. 2023 Aug 25;14(12):e00627. doi: 10.14309/ctg.0000000000000627

Figure 4.

Figure 4.

(a) CBPS-adjusted transplant-free survival by HRS reversal status for terlipressin vs midodrine plus octreotide. (b) CBPS-adjusted transplant-free survival by HRS reversal status regardless of treatment cohort. Sample sizes for adjusted results represent effective sample size after using CBPS reweighting. CBPS, covariate balancing propensity scoring; CI, confidence interval; HRS, hepatorenal syndrome.